Skip to main content
. 2022 Apr 23;12:6666. doi: 10.1038/s41598-022-10577-2

Figure 2.

Figure 2

Body weight of treatment groups. DIO-NASH mice were treated daily with vehicle (s.c.), ALT-801 (5 and 10 nmol/kg, s.c.), elafibranor (78 μmol/kg, oral) or semaglutide (10 nmol/kg, s.c.). Body weight was recorded daily. For ALT-801 and semaglutide, rapid body weight decreases occurred within 1–2 weeks and stabilized. Elafibranor (PPAR-α/δ agonist) causes weight loss in rodents but not in clinical trials. On day 63 vehicle animals were mis-dosed with ALT-801 10 nmol/kg, causing a rapid ~ 8% body weight decrease, which resolved over a period of days. ALT-801 treatment (10 nmol/kg) reduced body weight to the lean normal range (~ 30 g; − 25%). Data are expressed as mean ± SEM (n = 11–12). ***p ≤ 0.001 vs. vehicle control.